193 related articles for article (PubMed ID: 33007922)
1. Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate Cancer (PCa) Status.
Snider AJ; Seeds MC; Johnstone L; Snider JM; Hallmark B; Dutta R; Moraga Franco C; Parks JS; Bensen JT; Broeckling CD; Mohler JL; Smith GJ; Fontham ETH; Lin HK; Bresette W; Sergeant S; Chilton FH
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33007922
[TBL] [Abstract][Full Text] [Related]
2. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
[TBL] [Abstract][Full Text] [Related]
3. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer diagnosis and characterization with mass spectrometry imaging.
Kurreck A; Vandergrift LA; Fuss TL; Habbel P; Agar NYR; Cheng LL
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):297-305. PubMed ID: 29209003
[TBL] [Abstract][Full Text] [Related]
5. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
[TBL] [Abstract][Full Text] [Related]
6. Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer.
Kuvibidila S; Rayford W
J Lab Clin Med; 2006 Apr; 147(4):174-81. PubMed ID: 16581345
[TBL] [Abstract][Full Text] [Related]
7. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
9. Understanding the Relationship between Environmental Arsenic and Prostate Cancer Aggressiveness among African-American and European-American Men in North Carolina.
Parada H; Wu T; Fry RC; Farnan L; Smith GJ; Mohler JL; Bensen JT
Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33198142
[TBL] [Abstract][Full Text] [Related]
10. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.
Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
[TBL] [Abstract][Full Text] [Related]
11. Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
Falegan OS; Jarvi K; Vogel HJ; Hyndman ME
Prostate; 2021 Aug; 81(11):713-720. PubMed ID: 34097313
[TBL] [Abstract][Full Text] [Related]
12. Clinical presentation of prostate cancer in black South Africans.
Tindall EA; Monare LR; Petersen DC; van Zyl S; Hardie RA; Segone AM; Venter PA; Bornman MS; Hayes VM
Prostate; 2014 Jun; 74(8):880-91. PubMed ID: 24723425
[TBL] [Abstract][Full Text] [Related]
13. Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP.
Steck SE; Arab L; Zhang H; Bensen JT; Fontham ET; Johnson CS; Mohler JL; Smith GJ; Su JL; Trump DL; Woloszynska-Read A
PLoS One; 2015; 10(4):e0125151. PubMed ID: 25919866
[TBL] [Abstract][Full Text] [Related]
14. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
[TBL] [Abstract][Full Text] [Related]
15. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Serum Metabolomic Profiling Reveals Elevated Kynurenine Pathway's Metabolites in Humans with Prostate Cancer.
Khan A; Choi SA; Na J; Pamungkas AD; Jung KJ; Jee SH; Park YH
J Proteome Res; 2019 Apr; 18(4):1532-1541. PubMed ID: 30628444
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
[TBL] [Abstract][Full Text] [Related]
18. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of patients with and without prostate cancer using urine
Hasubek AL; Wang X; Zhang E; Kobus M; Chen J; Vandergrift LA; Kurreck A; Ehret F; Dinges S; Hohm A; Tilgner M; Buko A; Habbel P; Nowak J; Mercaldo ND; Gusev A; Feldman AS; Cheng LL
Magn Reson Chem; 2023 Dec; 61(12):740-747. PubMed ID: 37654196
[TBL] [Abstract][Full Text] [Related]
20. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker.
Qian X; Li C; Pang B; Xue M; Wang J; Zhou J
PLoS One; 2012; 7(5):e37225. PubMed ID: 22615945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
